Landmark Study Affirms The Clinical Utility of ImmunoCAP Allergy Testing

"Allergies Across America” Health Trends Report Published by Quest Diagnostics Spotlights the Importance of Allergy Diagnosis and Treatment to halt the allergic march to asthma, and to safely manage asthma symptoms.


Portage, MI—May 26, 2011—ImmunoCAP®, the worldwide leader of in vitro allergy diagnostics is pleased to present the results of the largest cross-sectional allergy study ever conducted.  The landmark study, announced today by Quest Diagnostics Incorporated, the world’s leading provider of diagnostic testing, information, and services, includes test results from over 2 million patients.  The data reveals important trends about the impact allergies have on patients of every age, socioeconomic group, and geographic region in the US.     

This wealth of information on allergies and asthma in the US was made possible by data collected from Quest Diagnostic’s use of the ImmunoCAP Specific IgE blood test from Phadia, the market leading in vitro allergy diagnostic test.  Quest Diagnostics and Phadia have partnered to improve the diagnosis and assessment of allergic disease for over 2 decades.  ImmunoCAP Specific IgE blood testing is conducted using a simple blood draw and has been helpful to primary care and specialist physicians who want to provide better care to their patients with allergies and asthma.  Phadia has maintained a strong commitment to the support and education of clinicians in the appropriate use of diagnostic tools to help with the diagnosis and management of allergy and autoimmune related diseases.  Phadia will utilize data from the Quest Diagnostics Health Trends Report to expand and extend the use of the ImmunoCAP Specific IgE blood test to support a guidelines-based approach to diagnosing and managing allergic diseases.

The Quest Diagnostics Health Trends Report™:  Allergies Across America™, confirms the “allergy march” in which early childhood food allergies heighten the risk for development of additional and more severe allergy-related conditions – including asthma – later in life.  In addition, the report shows that patients with asthma are 20% more likely to have an allergic component to their condition.  This confirms that allergy testing and exposure reduction to a patient’s specific allergic triggers are critically important steps to take for patients with asthma.

Other important findings include the prevalence of food allergies with infants and toddlers, compared to the prevalence of environmental allergies such as dust, ragweed, and mold that are more common with children and adults.

David Esposito, President and General Manager of Phadia US, says, “We commend Quest Diagnostics on their leadership role in spotlighting the impact of allergies in our nation.  This data enables us to work together to support health care reform initiatives that call for better patient care at reduced costs.  With full knowledge of their allergies and armed with an allergy or asthma action plan, patients can reduce unscheduled doctors’ office and emergency room visits, lessen the need for medications including costly inhaled corticosteroid/long-acting beta agonist combination medications, and minimize sick days that cause missed school or work.  Our hope is that this data is used by payers and policy makers to support and embrace the NIH Guidelines that recommend allergy testing for all patients with persistent asthma.”

Since August 2007 when the NIH funded Guidelines for the Diagnosis and Management of Asthma were last updated, the role of allergy testing and exposure reduction to specific allergic triggers in the care of asthma patients has been affirmed by these national guidelines.  With allergy testing and allergen exposure reduction programs in place, asthmatics can improve their quality of life, reduce asthma attacks, and decrease the need for medications.  However, these guidelines are still not being followed as closely as they should.  The data from the Quest Diagnostics Health Trends Report confirms that asthma patients and their caregivers should follow the guidelines and be tested for allergies and utilize the information gained from the test results to better manage this chronic disease.

About Phadia

Phadia is setting the standard as the world leader in specialty diagnostics for allergy and autoimmune related diseases.  As the world leader in specialty diagnostics, Phadia is committed to providing innovative diagnostic tools to help better manage patients with suspected allergy or a suspected autoimmune disorder.  ImmunoCAP® Specific IgE blood test is the assay of choice among specialists worldwide.  It is referenced and supported in over 3,000 scientific publications and in the most recently published Guidelines for the Diagnosis and Management of Food Allergy in the US. EliA® autoimmune assays are developed and optimized for Phadia® Laboratory Systems to provide exceptional sensitivity and specificity for the detection of disease-specific autoantibodies to aid in the diagnosis and management of autoimmune disorders.  In addition to the introduction of cutting edge diagnostics tools to support the delivery of Immune Response Diagnostics, Phadia is developing and making the benefits of ImmunoCAP® Molecular Allergy test results available to specialists worldwide to help improve the patient’s quality of life.  Contact Phadia today at 800.346.4364 or go to for Results You Can Trust.